NCT05909761View on ClinicalTrials.gov

Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy

RecruitingOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

September 16, 2024

Primary Completion Date

August 31, 2032

Study Completion Date

July 31, 2033

Conditions
Neuromyelitis Optica Spectrum DisorderPregnancy Related
Interventions
DRUG

UPLIZNA

Enrolled female participants with NMOSD who were exposed to UPLIZNA during pregnancy will be assessed. No study drug will be administered.

Trial Locations (1)

80045

RECRUITING

University of Colorado Denver, Aurora

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT05909761 - Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy | Biotech Hunter | Biotech Hunter